FDA Approved Weight Loss Medications 2026
FDA Approved Weight Loss Medications 2026: A Complete Guide
Reading time 8 min
The landscape of medically supported weight loss has changed more in the last 18 months than in the previous decade. Two new oral medications received FDA approval in late 2025 and early 2026, expanding the options available to people who want clinical-grade support alongside lifestyle changes — including, for the first time, a daily pill that rivals injectable GLP-1s in efficacy. If the article you read last year listed six FDA-approved options, that list needs updating. Here's where things stand today.
Why This Matters More Than It Sounds
Obesity is classified by the American Medical Association, the WHO, and the FDA as a chronic, relapsing disease — not a failure of willpower. The FDA has rigorously vetted every medication on this list through large-scale randomized controlled trials. What separates these from over-the-counter supplements is that the evidence is public, the mechanisms are documented, and the approval process requires proving both safety and efficacy in thousands of participants before a drug reaches a prescription pad.
None of these medications are a substitute for dietary change and physical activity. Every approval came with that caveat attached. What they can do — and what the trial data consistently shows — is make those lifestyle changes significantly more achievable and durable for people whose biology actively resists them.
The Six Original FDA-Approved Medications, Updated for 2026
Orlistat (Xenical / Alli)
The only weight loss medication available both by prescription (Xenical, 120 mg) and over the counter (Alli, 60 mg), orlistat works by blocking approximately 30% of dietary fat from being absorbed in the intestines. The unabsorbed fat passes through the digestive tract, which is also why high-fat meals while taking it produce well-documented gastrointestinal consequences — an effect that functions, unpleasantly but effectively, as a behavioral feedback loop. Clinical trials show average weight loss of 5–10% of body weight over the first year. It remains the only non-prescription FDA-approved option for weight management and is approved for adolescents aged 12 and older.
Phentermine-Topiramate (Qsymia)
Qsymia combines a stimulant appetite suppressant (phentermine) with an anticonvulsant that increases satiety (topiramate). The dual mechanism targets both the drive to eat and the sense of fullness — a combination that proved more effective in trials than either drug alone. Participants lost an average of 8–10% of body weight over 56 weeks in registration trials. It comes in escalating dose tiers, allowing physicians to titrate based on response and tolerability. It is not appropriate for people with cardiovascular disease, glaucoma, or hyperthyroidism, and requires monthly pregnancy testing in women of childbearing age due to teratogenicity risk. Approved for adolescents 12 and older.
Naltrexone-Bupropion (Contrave)
Contrave works on the brain's reward and hunger centers through a combination of naltrexone — an opioid antagonist — and bupropion, an antidepressant with dopaminergic activity. Together, they reduce both food cravings and the reward value that drives eating beyond hunger. It's particularly well-suited for people who eat in response to stress, boredom, or emotional cues rather than physiological hunger. Clinical data shows approximately 5–9% body weight reduction over one year. The bupropion component carries a black-box warning regarding suicidal thinking in younger patients, and it is contraindicated in people with seizure disorders or those currently using opioids.
Liraglutide (Saxenda)
Saxenda is a daily subcutaneous injection that mimics GLP-1, the gut hormone that slows gastric emptying, signals satiety to the brain, and regulates blood glucose. It was the first GLP-1 receptor agonist approved specifically for obesity management (as opposed to diabetes), and it remains an option for people whose physicians prefer a once-daily titration schedule. Average weight loss in trials was 5–12% of body weight over 56 weeks. It is approved for adolescents aged 12 and older with obesity. The weekly GLP-1 agents have largely surpassed it in efficacy benchmarks, but liraglutide remains in active use, particularly where access to newer agents is limited by supply or cost.
Semaglutide 2.4 mg Injectable (Wegovy)
Weekly injectable Wegovy remains the highest-efficacy single-agent injectable for obesity currently on the market. The STEP 1 trial published in the New England Journal of Medicine demonstrated average weight loss of 14.9% over 68 weeks — a magnitude previously associated only with bariatric surgery. Wegovy also carries a cardiovascular indication: the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in people with established cardiovascular disease and obesity. It's approved for adolescents 12 and older and remains the reference standard against which all newer obesity medications are compared.
Tirzepatide (Zepbound)
Approved in late 2023, Zepbound activates both GLP-1 and GIP receptors simultaneously — a dual-agonist mechanism that has produced the highest weight loss figures in any obesity pharmacotherapy trial to date. The SURMOUNT-1 trial showed average weight loss of 20.9% at the highest dose (15 mg) over 72 weeks, with approximately one-third of participants losing more than 25% of their body weight. It is administered once weekly by subcutaneous injection and is now among the most prescribed obesity medications in the United States. Supply constraints that plagued its early availability have largely resolved.
What's New: Two Oral Approvals That Change the Category
Oral Semaglutide 25 mg (Wegovy Pill) — Approved December 2025
For years, the primary barrier to GLP-1 therapy for many patients was the injection. In December 2025, the FDA approved Wegovy in tablet form — a 25 mg once-daily oral semaglutide — making it the first oral GLP-1 receptor agonist approved specifically for obesity management in adults. The OASIS 4 trial, a 64-week phase 3 randomized controlled trial, showed average weight loss of 13.6% compared to 2.2% with placebo — nearly equivalent to injectable Wegovy. It is the same active ingredient as the injectable, reformulated for oral delivery. One practical note: it must be taken in the morning on an empty stomach with a small amount of water, followed by a 30-minute fast before eating or drinking anything else. Patients who can manage that routine have access to GLP-1 efficacy without a needle.
Orforglipron (Foundayo) — Approved April 2026
On April 1, 2026, the FDA approved Foundayo (orforglipron), developed by Eli Lilly — the first small-molecule, nonpeptide oral GLP-1 receptor agonist approved for obesity. What distinguishes it from oral semaglutide is structural: because it is not a peptide, it is not degraded by stomach acid the same way and can be taken at any time of day, with or without food, with any beverage. No fasting window required. Phase 3 ACHIEVE trial data showed weight loss of 7.5% to 11.2% over 72 weeks depending on dose — meaningfully lower than tirzepatide or injectable semaglutide, but competitive for an oral agent with no administration restrictions. For patients whose adherence challenges are primarily about injection anxiety or morning routine complexity, Foundayo offers a genuine clinical alternative.
"The number of medications available to treat obesity has expanded rapidly. The growth is exciting because it provides more options to tailor treatment to an individual's health needs." — Dr. Ivania Rizo, M.D., DABOM, Director of Obesity Medicine, Boston Medical Center, spokesperson for The Obesity Society
How to Choose Between Them
No single medication is right for everyone, and these decisions belong in a physician-patient conversation — not a blog post. That said, a few practical frameworks are worth understanding before that conversation.
If maximum weight loss efficacy is the primary goal and injectable administration is acceptable, Zepbound (tirzepatide) currently leads the field in trial data. If cardiovascular risk reduction is an added priority, injectable Wegovy carries the documented CV outcomes indication from SELECT. For patients who want oral administration and can manage a morning fasting routine, oral Wegovy offers near-injectable efficacy. For patients who need a pill with no administration restrictions, Foundayo (orforglipron) is the most flexible option available, though its efficacy ceiling sits below the injectable class. For emotional or reward-driven eating patterns, Contrave's mechanism targets those pathways most directly.
What All of These Have in Common
Every medication on this list is a tool, not a cure. Clinical trials for all of them show significant weight regain when medication is stopped without lifestyle maintenance in place. The evidence base for these drugs is built on trials that combined pharmacotherapy with caloric reduction and physical activity — not medication alone. The most honest framing is that they lower the biological resistance to change, making dietary and behavioral modifications more achievable, not unnecessary.
All require a prescription. All carry side effect profiles that require physician evaluation. None are appropriate for people with certain cardiovascular, psychiatric, or gastrointestinal conditions without careful medical review. If you haven't worked with a physician who specializes in obesity medicine, that's the right starting point — not a prescription request based on something you read online.
The Takeaway
2025 and early 2026 delivered the most significant expansion of FDA-approved obesity pharmacotherapy since tirzepatide's arrival in 2023. The addition of two oral GLP-1 options — one with near-injectable efficacy, one with unmatched convenience — means that patients who previously declined or couldn't access injectable therapy now have real alternatives. The field is moving faster than most primary care physicians can track, which makes it worth going into those appointments informed. The eight medications above represent the current state of what the evidence and the FDA have validated. Everything else is a supplement with a marketing budget.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions
1. How many FDA-approved weight loss medications exist in 2026?
Eight, as of mid-2026: orlistat (Xenical/Alli), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), injectable semaglutide 2.4 mg (Wegovy), tirzepatide (Zepbound), oral semaglutide 25 mg (Wegovy pill, approved December 2025), and orforglipron (Foundayo, approved April 2026).
2. What is the newest FDA-approved weight loss medication?
Foundayo (orforglipron), approved by the FDA on April 1, 2026. It is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly that can be taken at any time of day with or without food — the first weight loss pill with no fasting or timing requirements.
3. Is the Wegovy pill as effective as the Wegovy injection?
Clinically close, but not identical. The OASIS 4 trial showed average weight loss of 13.6% with the 25 mg oral tablet over 64 weeks. Injectable Wegovy has shown approximately 14.9–16.6% weight loss in comparable timeframes. The pill requires a morning fasting window; the injection does not. For patients who can maintain that routine, the gap in efficacy is small.
4. What is the most effective FDA-approved weight loss medication in 2026?
By trial data, tirzepatide (Zepbound) — average weight loss of approximately 20.9% at the highest dose over 72 weeks in SURMOUNT-1, with roughly one-third of participants losing more than 25% of body weight. It is a weekly injectable dual GLP-1/GIP receptor agonist.
5. Can I take weight loss medication without diet and exercise changes?
Technically, but not effectively. Every FDA approval is based on trials that combined medication with caloric restriction and increased physical activity. The drugs lower the biological resistance to those changes — they don't eliminate the need for them. Stopping medication without lifestyle changes in place typically results in substantial weight regain.
6. Are any of these medications available as a pill rather than an injection?
Yes — three options: orlistat (available over the counter as Alli, or by prescription as Xenical), oral semaglutide 25 mg (Wegovy pill, approved December 2025, requires morning fasting), and orforglipron (Foundayo, approved April 2026, no timing restrictions). Qsymia and Contrave are also oral medications.
7. Which medication is best for people who also have type 2 diabetes?
GLP-1 and dual GLP-1/GIP receptor agonists — Saxenda, injectable Wegovy, and Zepbound — all improve blood glucose control alongside weight loss and are often preferred for patients with type 2 diabetes or prediabetes. Your physician and endocrinologist should guide this decision in the context of your current diabetes medications.
8. What are the most common side effects of GLP-1 weight loss medications?
Nausea, vomiting, diarrhea, and constipation are the most commonly reported side effects across all GLP-1 receptor agonists. These effects are typically most pronounced during dose escalation and diminish over time for most patients. Rare but serious risks include pancreatitis and, based on animal studies, thyroid C-cell tumors — a contraindication in people with personal or family history of medullary thyroid carcinoma or MEN2.
9. Are these medications covered by insurance in 2026?
Coverage varies significantly by plan and medication. GLP-1 medications for obesity remain inconsistently covered, though coverage has expanded as the cardiovascular outcomes data for semaglutide has strengthened the clinical case. Medicare Part D began covering anti-obesity medications for patients with cardiovascular disease following the SELECT trial results. Always verify your specific plan's coverage and prior authorization requirements.
10. Who qualifies for prescription weight loss medication?
FDA-approved weight loss medications are generally indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. Several are also approved for adolescents 12 and older. Qualification also depends on medical history, contraindications specific to each drug, and physician evaluation of the benefit-risk profile for your individual situation.